Clinical trials: Alzheimer's Type Dementia
Alzheimer's Disease
A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects
This is a randomized, double-blind (Investigator and subject-blinded) placebo-controlled, multiple, ascending-dose study to evaluate the safety, tolerability, and pharmacokinetic profile of BPN14770 in healthy young and elderly…
- Trial name
- NCT02840279
- Testing
- BPN14770
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Tetra Discovery Partners
Alzheimer's Disease, Dementia
Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease
The purpose of this study was to determine the safety and effectiveness of a relatively high dose of galantamine, 32 mg /day in a three-times daily dosage, compared with placebo in treating patients with Alzheimer's disease.
- Trial name
- NCT00338117
- Testing
- Galantamine hydrobromide
- Volunteers
- 554 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer Disease
Cognitive-Behavioral Treatment for Mild Alzheimer's Patients and Their Caregivers
The purpose of this study is to determine whether a comprehensive cognitive-behavioral therapy-based, multi-component treatment programme is effective in the treatment of neuropsychiatric symptoms of patients with mild…
- Trial name
- CBTAC (NCT01273272)
- Testing
- Comprehensive, CBT-based, multi-component treatment, Treatment as usual
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- University of Zurich
Patients Aged 65-85 (Both Included), Diagnosed of Mild Cognitive Impairment
Diabetes as an Accelerator of Cognitive Impairment and Alzheimer's Disease
This randomized controlled trial is aimed at studying the effects of an eHealth intervention on improving metabolic control and other cardiovascular risk factors (obesity, lipidic profile and hypertension) as the approach to…
- Conditions
- Patients Aged 65-85 (Both Included), Diagnosed of Mild Cognitive Impairment, Diagnosed of Type 2 Diabetes in Active Treatment (Hypoglycemic Agents) for a Period ≥5 Years
- Trial name
- DIALCAT (NCT03578991)
- Testing
- Smart pillbox, Interactive digital platform
- Where
- 8 sites in Spain
- Volunteers
- 54 people
- Sponsor
- Parc Sanitari Pere Virgili
Alzheimer's Disease
TNF-Alpha Inhibition for Treatment of Alzheimer's Disease
It is widely believed that inflammation contributes to the pathogenesis of AD. TNF has been implicated in both AD and neurological inflammation. Anti-TNF therapy is therefore surmised to be of potential benefit for treating AD.
- Trial name
- NCT00203359
- Testing
- etanercept given by perispinal administration
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Tobinick, Edward Lewis, M.D.
Dementia, Dysphagia
Family Caregiver Online Survey (Dementia and Swallowing Difficulties)
The Family Caregiver Survey is a one-time, 30-minute, online survey for people living with and caring for a family member with dementia.
- Conditions
- Dementia, Dysphagia, Dementia Alzheimers, Dementia, Vascular
- Trial name
- NCT06471660
- Where
- United States
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- University of Oregon
Alzheimer Type Dementia
Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia
The goal of this clinical study is to learn if the study drug DMB-I (INN: Latrepirdine) works to treat Alzheimer type dementia in adults. It will also learn about the safety of DMB-I (INN: Latrepirdine).
- Trial name
- NCT07251023
- Testing
- DMB-I (INN: Latrepirdine), Memantine Hydrochloride 20 MG
- Where
- 12 sites in Russia
- Volunteers
- 450 people
- Sponsor
- Bigespas LTD
Alzheimer's Type Dementia
A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia
The purpose of this study is to compare 23 mg donepezil sustained release (SR) to the currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with severe Alzheimer's disease.
- Trial name
- NCT01276353
- Testing
- E2020
- Where
- 11 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Eisai Inc.
Caregiver Stress, Dementia
A Study of Caregiver Connections Via Technology in Dementia
This research is being done to develop a unique matching process for caregivers of persons living with dementia, such as Alzheimer's disease, Lewy body dementia, frontotemporal degeneration, or other dementia syndromes.
- Conditions
- Caregiver Stress, Dementia, Alzheimer Disease, Lewy Body Dementia
- Trial name
- NCT05779839
- Testing
- Algorithm, Random Match
- Where
- United States
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Alzheimer's Disease
TNF-Alpha Inhibition for Treatment of Alzheimer's Disease
It is widely believed that inflammation contributes to the pathogenesis of AD. TNF has been implicated in both AD and neurological inflammation. Anti-TNF therapy is therefore surmised to be of potential benefit for treating AD.
- Trial name
- NCT00203320
- Testing
- etanercept given by perispinal administration
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Tobinick, Edward Lewis, M.D.
Alzheimers Disease, Dementia
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation.
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU (NCT05552157)
- Testing
- Remternetug (SC)
- Where
- 37 sites in United States, Argentina and 13 more
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Caregiver Stress, Dementia
A Study to Evaluate Caregiver Connections Via Technology for Patients With Alzheimer's and Other Types of Dementia
This research is being done to develop a unique matching process for caregivers of persons living with dementia, such as Alzheimer's disease, Lewy body dementia, frontotemporal degeneration, or other dementia syndromes.
- Conditions
- Caregiver Stress, Dementia, Alzheimer Dementia, Lewy Body Dementia
- Trial name
- NCT05497817
- Testing
- Algorithm, Random Match
- Volunteers
- healthy volunteers welcome
- Sponsor
- Mayo Clinic
Alzheimer's Disease, Dementia
Brain Study of Patients With Frontal Lobe Dementia and Parkinsonian Disorders
The Cognitive Neuroscience Section of the National Institute of Neurological Disorders and Stroke proposes to continue its cross-sectional and longitudinal studies of cerebral metabolism in frontal lobe dementias and atypical…
- Conditions
- Alzheimer's Disease, Dementia, Down's Syndrome
- Trial name
- NCT00001178
- Where
- United States
- Volunteers
- 597 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Agitation Associated With Dementia of the Alzheimer's Type
Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
To evaluate the safety of brexpiprazole 1 mg or 2 mg after a 14 week treatment regimen for agitation associated with dementia of the Alzheimer's type patients who completed in a double-blind trial, and to investigate the efficacy…
- Trial name
- NCT03724942
- Testing
- Brexpiprazole
- Where
- Japan
- Volunteers
- 164 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Alzheimer's Disease, Dementia
A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of NIC5-15 in the treatment of Alzheimer's Disease.
- Trial name
- NCT01928420
- Testing
- Drug: NIC5-15
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Humanetics Corporation
Dementia of Alzheimer Type, Alzheimer Disease
Prevalence of Alzheimer's Disease Pathology in the Community
The goal of this observational study is to (I) study the proportion of people with Alzheimer's disease pathology in a large Norwegian population-based cohort of people aged 70 years or older and to (II) study longitudinal changes…
- Conditions
- Dementia of Alzheimer Type, Alzheimer Disease, Mild Cognitive Impairment, Pathology
- Trial name
- HUNT4AD (NCT06719453)
- Volunteers
- 9,663 people, healthy volunteers welcome
- Sponsor
- Helse Stavanger HF
Mild, Moderate, or Severe Alzheimer's Disease
A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients
An open-label, exploratory, phase II, proof-of concept, clinical study to assess the safety and tolerability of EI-1071 and the effects of EI-1071 on neuroinflammation in patients with mild, moderate, or severe Alzheimer's disease
- Trial name
- NCT06745583
- Testing
- EI-1071 tablet, oral
- Where
- 2 sites in Taiwan
- Volunteers
- 7 people
- Sponsor
- Elixiron Immunotherapeutics Inc.
Alzheimer Dementia (AD), Diabete Type 2
Brain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study
Alzheimer's disease is the most common cause of dementia and affects a growing number of older adults. Although harmful proteins build up in the brain, we still do not fully understand why some brain regions are affected earlier…
- Trial name
- PETTAU (NCT07482072)
- Testing
- [18F]FDG PET, [11C]PIB
- Where
- Denmark
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Alzheimer's Disease
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of…
- Trial name
- MissionAD1 (NCT02956486)
- Testing
- Elenbecestat
- Where
- 258 sites in United States, Argentina and 16 more
- Volunteers
- 2,212 people
- Sponsor
- Eisai Co., Ltd.
Alzheimer's Disease
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose.
- Trial name
- REFLECT-3 (NCT00348140)
- Testing
- Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg
- Where
- 194 sites in United States, Australia and 20 more
- Volunteers
- 1,468 people
- Sponsor
- GlaxoSmithKline